Shares of Moderna (MRNA) jumped by a staggering 38.53% in 30 days from $156.96 to $217.44 at 20:51 EST on Wednesday, following the last session’s downward trend. NASDAQ Composite (MRNA) is falling 0.09% to $13,911.75, following the last session’s downward trend,

Moderna’s last close was $213.00, 6.46% under its 52-week high of $227.71.

Volume

Today’s last reported volume for Moderna is 7981547 which is 15.14% below its average volume of 9405634.

Moderna’s Sales

Moderna’s sales growth is 6546% for the ongoing quarter and 7125.9% for the next. The company’s growth estimates for the current quarter and the next is 2100% and 1428.8%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 3960.8%, now sitting on 803.4M for the twelve trailing months.

Volatility

Moderna’s last week, last month’s, and last quarter’s current volatility was 2.83%, 1.03%, and 3.60%, respectively.

Moderna’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.83% (last week), 2.58% (last month), and 3.60% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Moderna’s stock is considered to be oversold (<=20).

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $217.44 at 20:51 EST, under its 52-week high of $227.71 and way above its 52-week low of $54.21.

Moderna’s Moving Average

Moderna’s worth is way above its 50-day moving average of $173.68 and way above its 200-day moving average of $150.56.

Previous days news about Moderna (MRNA)

Moderna submits for marketing approval of Covid-19 vaccine in adolescents in Europe. According to Market Watch on Monday, 7 June, "Shares of Moderna Inc. rose 0.5% in premarket trading Monday, after the biotechnology company said it had submitted for conditional market approval (CMA) with the European Medicines Agency (EMA) for its COVID-19 vaccine in adolescents, ages 12 to less than 18. ", "We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents," said Chief Executive Stéphane Bancel. "

Moderna seeks conditional OK to vaccinate adolescents in Europe. According to MarketWatch on Monday, 7 June, "Shares of Moderna Inc. rose 0.5% in premarket trading Monday, after the biotechnology company said it had submitted for conditional market approval (CMA) with the European Medicines Agency (EMA) for its COVID-19 vaccine in adolescents, ages 12 to less than 18. ", "We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents," said Chief Executive Stéphane Bancel. "

Moderna submits for CMA for Covid-19 vaccine in adolescents with EMA – quick facts. According to Business Insider on Monday, 7 June, "The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults.", "The COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center."

Moderna files for authorization for Covid-19 vaccine in adolescents with health Canada. According to Business Insider on Monday, 7 June, "The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults.", "The COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center."

Moderna talking to U.S. about shots for low-income countries. According to Bloomberg Quint on Wednesday, 9 June, "Both the Moderna and the Pfizer vaccines require two doses given several weeks apart to provide maximum protection from the coronavirus."

More news about Moderna (MRNA).

LEAVE A REPLY

Please enter your comment!
Please enter your name here